Data protection Impressum

Life sciences

iOnctura has secured EUR 80 million in a Series B funding round to advance innovative cancer therapies, with a focus on neglected cancers such as uveal melanoma.

iOnctura secures EUR 80 million Series B financing to advance cancer treatments

25 June 2024

Thego.care has launched an online store for innovative medical armbands to enhance patient comfort and care.

Thego.care launches an online store for its innovative medical armbands

24 June 2024

SensArs, an EPFL spin-off specialized in neuromodulation technology for treating chronic pain and sensory loss, has secured a pre-seed investment from HTH and two grants worth EUR 1.1 million.

SensArs secures EUR 1.1 million to advance neuromodulation technology

17 June 2024

Aktiia has received CE mark approval for its non-cuff optical technology, enabling the start-up to access markets in over 40 countries.

Aktiia’s CE Mark approval opens doors to international expansion

17 June 2024

Dandelion Science and the Wyss Center Geneva have announced a partnership to develop a generative AI platform for non-invasive brain therapies.

Dandelion Science partners with Wyss Center to pioneer AI-based brain therapies

12 June 2024

Vaud-based life sciences company Limula has secured CHF 6.2 million to democratize access to life-saving cell and gene therapies.

Limula secures CHF 6.2 million to advance automated cell therapy platform

21 May 2024

HeroSupport and Calico Biosystems join Tech4Eva, a six-month equity-free accelerator dedicated to advancing women’s health technologies globally.

HeroSupport and Calico Biosystems selected for the Tech4Eva accelerator program

15 May 2024

ORamaVR is set to enhance its innovative VR solutions for medical training with new support from Innosuisse's Scale-up Coaching program.

ORamaVR receives Scale-up Award from Innosuisse to accelerate growth

15 May 2024

Takeda will receive an exclusive option to license AC Immune's ACI-24.060, a breakthrough therapy to combat the progression of Alzheimer's disease, for an upfront payment of USD 100 million and potential milestone payments of USD 2.1 billion.

AC Immune and Takeda sign USD 100 million deal to treat Alzheimer’s disease

13 May 2024

Ikerian AG, along with its subsidiary RetinAI, has successfully completed a USD 6.18 million Series A extension financing round to propel the development and commercial rollout of innovative medical technologies.

Ikerian, parent company of RetinAI, secures USD 6.18 million for AI-driven medical advancements

13 May 2024

1 … 8 9 10 11 12 13 14 15 16 … 43